Literature DB >> 32122652

Hypoxia training improves hepatic steatosis partly by downregulation of CB1 receptor in obese mice.

Qin Yang1, Shunli Sun2, Wei Liu3, Qingguang Liu4, Jibing Wang5.   

Abstract

Hypoxia training (HT) can reduce body weight and improve fatty liver. However, the mechanism is not clear. A previous study indicated that HT-induced weight loss might be associated with the endocannabinoid system (ECS), which has also been reported recently to be involved in the persistent lipid mediators after weight loss. The present study investigated the effects of HT, a new prospective weight-loss method, on nutritionally obese mice and demonstrated that HT significantly reduced body weight, fat mass, transcriptional expression of liver endocannabinoid receptor 1 (CB1), biosynthetic enzyme diacylglycerol lipase α (DAGLα) and improved the transcriptional expression of degrading enzyme monoacylglycerol lipase (MAGL). Liver endocannabinoids 2-arachidonoylglycerol (2-AG) but not anandamide (AEA) was evidently decreased in response to HT. Simultaneously, HT significantly reduced liver index, serum alanine aminotransferase (ALT) and liver fat contents. Western blot showed decreased expression of liver CB1, sterol regulatory element-binding protein-1 (SREBP-1), peroxisome proliferator-activated receptor γ (PPARγ) and increased expression of adipose triglyceride lipase (ATGL) and carnitine palmitoyltransferase-1 (CPT-1) levels after HT. However, intraperitoneal injection of CB1 receptor agonist WIN55212-2 offset the benefits by which HT reduced hepatic fat synthesis, with significant increased protein expression of SREBP-1 and PPARγ. Taken together, these findings reported the alleviation of obesity and hepatic steatosis through HT and provided a putative molecular mechanism by inhibiting the CB1-mediated fat synthesis.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CB1; Hypoxia training; Lipid metabolism; Liver; PPARγ; SREBP-1

Mesh:

Substances:

Year:  2020        PMID: 32122652     DOI: 10.1016/j.bbrc.2020.02.134

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Cannabinoid Receptor 1 Antagonism Demonstrates High Therapeutic Potential for the Treatment of Primary Sclerosing Cholangitis.

Authors:  Lindsey Kennedy; Gianfranco Alpini
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-02-04

Review 2.  Monoacylglycerol lipase reprograms lipid precursors signaling in liver disease.

Authors:  Matteo Tardelli
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.